邯郸月经量少怎么办邯郸看妇科病医院,邯郸老婆总胎停应该怎么治,邯郸玛丽亚在哪儿,邯郸阴道里疙瘩白带,邯郸月经推迟吃什么调理好,邯郸怀孕几天会有妊娠反应,邯郸怀孕医院检查时间

BEIJING, Aug. 22 (Xinhuanet) -- U.S. presidential candidate Rick Perry's controversial stem-cell treatment may inspire desperate patients to follow his lead while causing medical and legal concerns, according to media reports Monday.The Texas governor underwent a procedure on July 1 where stem cells, made from fat taken from his body, were put into his bloodstream to see if they might find their way to fix a bad back.The treatment carries potential risks ranging from blood clots to infection to cancer and may even run afoul of federal rules, doctors say. File photo of U.S. Republican presidential candidate Texas Governor Rick Perry."As a highly influential person of power, Perry’s actions have the unfortunate potential to push desperate patients into the clinic of quacks,” Harvard’s stem cell expert George Daley told the Associated Press.Worries about the safety and wisdom of this treatment are widespread among stem cell researchers as such a treatment has not been thoroughly vetted by researchers or approved by the FDA.

BEIJING, Sept. 28 (Xinhua) -- Chinese State Councilor Liu Yandong met here on Wednesday with Paul Otellini, president and chief executive officer (CEO) of U.S. computer chip giant Intel Corp.Liu praised Intel's development strategy of expanding investment in China and showed appreciation for the company's support of the development of China's education sector as well as its commitment to good corporate citizenship.She briefed Otellini on China's 12th Five-Year Plan, the recent developments in education and the mechanism for China-U.S. High-level Consultation on People-to-People Exchange.Chinese State Councilor Liu Yandong (R) meets with Paul Otellini, president and chief executive officer (CEO) of U.S. computer chip giant Intel Corp, in Beijing, capital of China, Sept. 28, 2011.She said bilateral people-to-people exchanges have made great achievements, with extensive consensuses reached on cooperation in the areas of education, science and technology, culture, sports, women and youth in the last two years.She hoped Intel will give full play to its advantages and deepen cooperation with China's Ministry of Education, so as to make new contributions to bilateral people-to-people exchanges.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

THE HAGUE, Aug. 16 (Xinhua) -- ESBL-enzymes, which are known for their ability to stop the effects of antibiotics, can directly pass from chicken to people, said a research published on Tuesday.Veterinary researcher Dik Mevius of the Wageningen University released the finding in the magazine Resource.The research group led by Mevius has isolated six ESBL-genes varieties and compared them to bacteria found on hospital patients, on super market poultry and in laying batteries. In 35 percent of all cases, they discovered a match of 100 percent.Bacteria like Klebsiella on E. coli can produce the ESBL-enzymes. A healthy person will not feel any effect, but people with a lower immune system can get very sick. In areas like a hospital, the infection can easily spread."The main concern is that the enzyme resists the most used antibiotics, which makes the treatment of infected persons difficult," said Mevius.According to Mevius, 94 percent of supermarket poultry carries the enzyme, but all enzymes will be killed during the heating process of cooking.